by administrator | Oct 2, 2018 | Appili Therapeutics, News
See the original post here. HALIFAX, Nova Scotia, October 1, 2018 – Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, has named Dr. Armand Balboni as its first Chief Scientific...
by administrator | Jul 30, 2018 | Appili Therapeutics, News
See original article here New Antibiotic Formulation Designed to Treat Parasitic and Anaerobic Bacterial Infections; Appili Will Use Study Data as Basis for NDA Filing HALIFAX, Nova Scotia, July 30, 2018 – Appili Therapeutics Inc. (the “Company” or “Appili”) announced...
by administrator | Apr 18, 2018 | Appili Therapeutics, News
See original story here Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that it will participate in this year’s annual Bloom Burton & Co. Healthcare Investor Conference....
by administrator | Feb 8, 2018 | Appili Therapeutics, News
See original story here Halifax drug discovery company Appili Therapeutics Inc., has raised $4.3 million in equity financing to further its operations and add to its number of drug candidates. The company said in a press release it raised the money through a private...
by administrator | Jan 9, 2018 | Appili Therapeutics, News
See original Entrevestor post here Appili Therapeutics has struck an agreement to work on a vaccine that could protect people against a potential bioterror threat. The Halifax drug discovery company said Monday it signed a licence agreement with the National Research...
